Heparin-Induced Thrombocytopenia: Prevalence in a Large Cohort of Patients and Confirmed Role of PF4/Heparin Complex as the Main Antigen for Antibodies

Abstract

We performed a retrospective study on the prevalence of heparin-induced thrombocytopenia (HIT) in 233 patients receiving hog mucosa heparin therapy. Of these, 82 patients received s.c. calcium heparin, 130 patient received unfractionated (UF) i.v. heparin, and 21 patients received low molecular weight heparins (LMWH). An additional four patients, referred to our consultation and diagnosed by us as having clinically active type II HIT (HIT-II) were also studied. The mean platelet count of the 233 patients receiving heparin showed a significant decrease after 2 days of heparin treatment and a following significant increase 6 days later (basal: 257 ± 147 x 10⁹ platelets/L; day 2: 239 ± 122, p < 0.0002; day 6: 286 ± 119, p < 0.004). Of the 212 patients receiving UF heparin, 13 (6%) fulfilled the criteria for HIT-II: seven of these had received i.v. heparin (mean daily dose 26,600 ± 4,082 IU ± SD) and six had received s.c. heparin (mean daily dose 21,428:t 6,900 IU). Their mean basal platelet count was 226 ± 100 SD × 10⁹ platelets/L and the nadir during heparin treatment was 78 ± 39 x 10⁹ platelets/L. Thrombotic complications occurred in four (30.7%) of the 13 patients with HIT-II. Since the immunological mechanism has been demonstrated for HIT-II and since platelet factor 4 (PF4) was identified as the co-factor for the binding of heparin-related antibodies, we set up our own enzyme-linked immunosorbent assay (ELISA) for testing antibodies against PF4/heparin complex bound through electrostatic bridges to the solid phase. The highest binding capacity of HIT-related IgG to the multimolecular complex was obtained at 20 μg/ml for PF4 and 3 μg/ml for heparin, corresponding to 250 ng of PF4 and 42 ng of heparin in each microtiter well. Such binding was inhibited in a dose-dependent manner by increasing amounts of heparin, protamine hydrochloride, and a monoclonal antibody anti-human PF4 clone 1OB2. We observed that HIT-related antibodies bound also to PF4/LMWH complexes but the optimal PF4/glycosaminoglycan ratio appeared more critical for LMWH (enoxaparin, fraxiparin, and pamaparin) than for UF heparin. Sera from eight patients with HIT-II were tested by PF4/heparin ELISA; six of these had IgG against the complex PF4/heparin and three also had IgM. The persistence of HIT-related antibodies was investigated in three patients: in one such antibodies were still detectable 3 years after the acute episode, while in the other two, they disappeared after 6 months and 1 year, respectively. Key Words: Heparin-related anti body—Platelet factor 4 (PF4)—Heparin—Low molecular weight heparin—Thrombocytopenia—Thrombosis.

Get full access to this article

View all access options for this article.

References

Davey MG , Lander H. Effect of injected heparin on platelet levels in man. J Clin Pathol 1968;21:55.

Zucker MB Biological aspects of heparin action. Heparin and platelet function. Fed Proc 1977:36:47.

Warkentin TE , Kelton JG Heparin and platelets. Hematol Oncol Clin North Am 1990;4:243.

Bailey RT , Ursick JA , Heim KL , Hilleman DE , Reich JW

Heparin-associated thrombocytopenia: a prospective comparison of bovine lung heparin, manufactured by a new process, and porcine intestinal heparin. Drug

Int Clin Pharm 1986;20:374.

Rhodes GR , Dixon RH , Silver D. Heparin-induced thrombocytopenia with thrombotic and hemorrhagic manifestation . Surg Gyn Obst 1973;136:409.

Green D. Harris K , Reynolds N. , Roberts M. , Patterson R. Heparin immune thrombocytopenia: evidence for a heparin-platelet complex as the antigenic determinant. J Lab Clin Med 1978,91:167.

Lynch DM , Howe SE Heparin-associated thrombocytopenia: antibody binding specificity to platelet antigens. Blood 1985;5:1176.

Kelton JG , Sheridan D. , Santos A. et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988;72:925.

Chong BH , Ismail F. , Chesterman CN , Berndt MC Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 1989 ;73: 235.

10.

Anderson GP Insights into heparin-induced thrombocytopenia . Br J Haematol 1992;80:504.

11.

Greinacher A. , Michels I. , Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemostas 1992;67:545.

12.

Amiral J. , Bridey F. , Dreyfus M. , Vissa AM , Fressinaud E. , Wolf M. , Meyer D. Platelet factor 4 complexed to heparin is the target for the antibodies generated in heparin-induced thrombocytopenia. Thromb Haemostas 1992;68:95.

13.

Greinacher A. , Potzsch B. , Amiral J. , Dummel V. , Eicher A. , Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemostas 1994;47:247.

14.

Kelton JG , Smith JW , Warkentin TE , Hayward Cpm , Denomme GA Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994;83:3232.

15.

Visentin GP , Ford SE , Scott PJ , Aster RH Antibodies from patients with heparin-induced thrombocytopenia-thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994;93:81.

16.

Greinacher A. , Amiral J. , Dummel V. , Vissac A. , Kiefel V. , Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4-heparin enoyme-linked immunosorbent assay. Transfusion 1994:34:381.

17.

Saggin L. , Cazzola F. , Corona G. , Salvatico E. Cella G , Prosdocimi M. Neutralization of the antiheparin activity of platelet factor 4 by a monoclonal antibody. Thromb Haemostas 1992;67:137.

18.

Weismann RE , Tobin RW Arterial embolism occurring during systemic heparin therapy, Arch Surg, 1958;76:219,

19.

Natelson EA , Lynch EC , Alfiey CP Jr, Gross JB Heparin-induced thrombocytopenia: an unexpected response to treatment of consumption coagulopathy. Ann Intern Med 1969;71:1121.

20.

Eika C. Anticoagulant and platelet aggregation activities of heparin. Thromb Res 1973:2:349.

21.

Lindon J. , Rosemberg R. , Merril R. , Salzman E. Interaction of human platelets with heparinized agarose get. J Lab Clin Med 1978:91:47.

22.

Fabris F. , Fussi F. , Casonato A. , Visentin L. Randi M. , Smith MR Girolami A. Normal and low molecular weight heparins: interaction with human platelets . Eur J Clin Invest 1983:13:135.

23.

Gollub S. , Ulin AW Heparin-induced thrombocytopenia in man. J Lab Clin Med 1962;59:430.

24.

King DJ , Kelton JG Heparin-associated thrombocytopenia, Ann Intern Med 1984; 100:535.

25.

Warkentin TE , Keiton JG Heparin-induced thrombocytopenia. Ann Rev Med 1989;40:31.

26.

Kelton JG , Levine MN Heparin-induced thrombocytopenia. Semin Thromb Hemostas 1986; 12:59.

27.

Chong BH Heparin-induced thrombocytopenia. Blood Rev 1988; 2: 108.

28.

Phelan BK Heparin-associated thrombosis without thrombocytopenia. Ann Intern Med 1983;99:637.

29.

Lassepas MR , Cipolle RJ , Rodvold KA Heparin induced thrombocytopenia in patients with cerebrovascular ischemic disease. Neurology 1984;34:736.

30.

Roberts B. , Rosato FE , Rosato EF

Heparin: a cause of arterial emboli?

Surgery 1964;55:803.

31.

Levy G. , Levy PY , Jamet M. , Toroyan P. Thrombopenie induite par une heparine de bas poids moleculaire au cours d'un traiement hypotenseur et diuretique: coincidence ou relation. Ann Fr Anesthiol Reanim 991; 10:586.

32.

Metz D. , Guyen N. , Chapoutot J. , et al. Embolie pulmonaire massive revelant une thrombopenie induite par eparine de bas poids moleculaire: succes therapeutique d'une prostacyctine . Ann Cardiol Angiol 1991;40:619.

33.

Warkentin TE , Levine MN , Hirsh J. , et al. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin . N Engl J Med 1995;18:1330.

34.

Amiral J. , Bridey F. , Wolf M. , et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin induced thrombocytopenia: a study of 44 cases. Thromb Haemostas 1995;73:21.

35.

Greinacher A. , Michels I. , Kiefel V. , Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemostas 1991;66:734.

36.

Chong BH , Ismail F. , Cade J. , Gallus AS , Gordon S. , Chesterman CN Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 1989;73:1952.

37.

Keeling DM , Richards EM , Baglin TP Platelet aggregation in response to four low molecular weight heparins and the heparinoid ORG 10172 in patients with heparin-induced thrombocytopenia . Br J Haematol 1994;86:425.

38.

Denton J. , Lane DA , Thunberg L. , Slater AM , Lindahl U. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J 1983; 209:455.

39.

Patrassi GM , Luzzatto G. Heparin-induced thrombocytopenia with thrombosis of the aorta, iliac arteries and right axillary vein successfully treated by low-molecular weight heparin. Acta Haematol 1994;91:55.

40.

Amiral J. , Peynaud-Debayle E. , Wolf M. , Bridey F. , Vissac AM , Meyer D. Generation of antibodies to Heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am J Hematol 1996;52:90.